Marshall Wace’s Silence Therapeutics SLN Stock Holding History

Marshall Wace’s Portfolio SLN Stock Details SLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$894K	Buy	169,616 +13,936	+9%	+$76.7K	﹤0.01%	2191
2025 Q4	$947K	Buy	155,680 +72,461	+87%	+$464K	﹤0.01%	1958
2025 Q3	$432K	Sell	83,219 -92,643	-53%	-$515K	﹤0.01%	2288
2025 Q2	$1.02M	Sell	175,862 -52,556	-23%	-$225K	﹤0.01%	1835
2025 Q1	$644K	Sell	228,418 -260,471	-53%	-$1.27M	﹤0.01%	1963
2024 Q4	$3.36M	Buy	488,889 +320,472	+190%	+$4.14M	﹤0.01%	1234
2024 Q3	$3.06M	Buy	168,417 +19,020	+13%	+$354K	﹤0.01%	1205
2024 Q2	$2.84M	Buy	149,397 +10,206	+7%	+$217K	﹤0.01%	1215
2024 Q1	$3.01M	Buy	+139,191	New	+$3.03M	﹤0.01%	1195

Other funds holding SLN

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Marshall Wace's SLN Position: Q1 2026 in Review

Marshall Wace increased its Silence Therapeutics (SLN) stake by 9% in Q1 2026, buying an estimated $76.7K and bringing the position to 169,616 shares worth $894K. The position accounts for ﹤0.01% of the portfolio, ranked #2191.

Marshall Wace first reported a position in SLN in Q1 2024 and has held it in 9 quarters since. The position peaked at $3.36M in Q4 2024. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

Marshall Wace held 169,616 shares of Silence Therapeutics worth $894K as of Q1 2026.
Marshall Wace bought 13,936 Silence Therapeutics shares in Q1 2026, an estimated $76.7K.
Silence Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2191 holding.
Marshall Wace first reported a position in Silence Therapeutics in Q1 2024 and has held it in 9 quarters since.
Marshall Wace's Silence Therapeutics position peaked at $3.36M in Q4 2024.
56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.